589 related articles for article (PubMed ID: 25887462)
1. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.
Parkins MD; Rendall JC; Elborn JS
Chest; 2012 Feb; 141(2):485-493. PubMed ID: 21835906
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
4. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
6. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.
Chin M; De Zoysa M; Slinger R; Gaudet E; Vandemheen KL; Chan F; Hyde L; Mah TF; Ferris W; Mallick R; Aaron SD
J Cyst Fibros; 2015 Jul; 14(4):482-9. PubMed ID: 25544473
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
[TBL] [Abstract][Full Text] [Related]
11. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.
Yau YC; Ratjen F; Tullis E; Wilcox P; Freitag A; Chilvers M; Grasemann H; Zlosnik J; Speert D; Corey M; Stanojevic S; Matukas L; Leahy TR; Shih S; Waters V
J Cyst Fibros; 2015 Mar; 14(2):262-6. PubMed ID: 25453872
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
15. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
[TBL] [Abstract][Full Text] [Related]
16. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
Stressmann FA; Rogers GB; Marsh P; Lilley AK; Daniels TW; Carroll MP; Hoffman LR; Jones G; Allen CE; Patel N; Forbes B; Tuck A; Bruce KD
J Cyst Fibros; 2011 Sep; 10(5):357-65. PubMed ID: 21664196
[TBL] [Abstract][Full Text] [Related]
17. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
18. Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
Skolnik K; Nguyen A; Thornton CS; Waddell B; Williamson T; Rabin HR; Parkins MD
BMC Infect Dis; 2017 Oct; 17(1):660. PubMed ID: 28969684
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]